RECELL
Commercial- Indications
- Thermal burns, Full-thickness skin defects
Company intelligence / Profile preview
The company has achieved positive results in multiple clinical trials, including a pivotal trial for vitiligo treatment that met its primary effectiveness endpoint of super-superiority in 2022[6], and a pivotal trial for soft-tissue injuries showing statistically superior donor sparing and comparable healing rates[9].
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Avita Medical, Inc..